Evidence method
Level · gp.fundamentals.capex_revenue_ratio
7.88% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Mar 31, 2023
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001493152-23-016392General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-471.17% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
95.01% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-278.37% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
175.40% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
43.21% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 2.81%
- Current
- 7.88%
- Delta
- 5.07%
- Previous
- 7.20%
- Current
- -471.17%
- Delta
- -478.37%
- Previous
- 95.05%
- Current
- 95.01%
- Delta
- -0.04%
- Previous
- -153.17%
- Current
- -278.37%
- Delta
- -125.21%
- Previous
- 95.13%
- Current
- 175.40%
- Delta
- 80.27%
- Previous
- 29.16%
- Current
- 43.21%
- Delta
- 14.05%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LCTX Fundamental State →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CAPEX_INTENSITY_INCREASED →Transitioned To · LCTX CASH_GENERATION_DECREASED →Transitioned To · LCTX MARGIN_DECREASED →Transitioned To · LCTX PROFITABILITY_DECREASED →Transitioned To · LCTX R_AND_D_INTENSITY_INCREASED →Transitioned To · LCTX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.